Table 1.
Patient and tumor characteristics
| Characteristic | Values (n = 56 patients) |
|---|---|
| Age | |
| Median, range | 40 (23–74) |
| Tumor stage | |
| 1 | 5 (9) |
| 2 | 40 (71) |
| 3 | 7 (13) |
| 4 | 4 (7) |
| Nodal stage | |
| Lymph nodes negative | 19 (34) |
| Lymph nodes positive | 37 (66) |
| Grade | |
| II | 18 (32) |
| III | 34 (61) |
| Not determined | 4 (7) |
| Chemotherapy | |
| 6 × dose dense doxorubicin/cyclophosphamide | 43 (77) |
| 3 × dose dense doxorubicin/cyclophosphamide, 3 × docetaxel/capecitabine | 5 (9) |
| 4 × dose dense doxorubicin/cyclophosphamide, 2 × cyclophosphamide/thiotepa/carboplatin | 8 (14) |
| BRCA germline mutation status (Sanger sequencing) | |
| BRCA1 mutation | 10 (18) |
| BRCA2 mutation | 2 (4) |
| Wildtype | 39 (70) |
| Not determined | 5 (9) |
| BRCA1 promoter methylation | |
| No BRCA1 methylation | 39 (70) |
| BRCA1 methylation | 17 (30) |
| Response breast and lymph nodes | |
| No pathological complete remission | 31 (55) |
| Pathological complete remission | 25 (45) |
| Relapse | |
| No relapse | 47 (84) |
| Relapse | 9 (16) |
Values are n (%) unless stated otherwise